mRNAワクチン(感染症):世界の市場機会分析・予測

◆英語タイトル:MarketVIEW: mRNA vaccines (infectious diseases) - mMRNA vaccines: landscape overview and pipeline analysis
◆商品コード:VAZ2006015
◆発行会社(リサーチ会社):VacZine Analytics
◆発行日:2019年1月
◆ページ数:n/a
◆レポート言語:英語
◆レポート形式:Executive presentation (120 slides, .pdf) + 1 MS Excel
workbook (.xls)
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Region PriceUSD8,995 ⇒換算¥935,480見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はVacZine Analytics社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
VacZine Analytics社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

‘Nucleic acid-based therapeutics’ based on mRNA, are a group of technologies with potential applications in vaccination for cancer, infectious diseases and diseases requiring protein replacement therapy. Improvements in mRNA formulation and delivery using lipid nanoparticle and cationic nanoparticle encapsulation have overcome early issues with stability and complex dendritic cell (DC) loading techniques. Landmark studies have shown that directly injected encapsulated mRNA is both safe and immunogenic triggering humoral and cellular immune responses in healthy and cancer patients.
mRNA vaccines are potentially disruptive because they provide some critical advantages over existing vaccine antigen approaches.

This MarketVIEW product consists of a detailed Executive presentation (~120 .pdf slides) and MS-Excel workbook (.xls) which gives a comprehensive overview of mRNA technologies and their potential application in the prophylatic and therapeutic setting for cancer and infectious diseases indications. An R&D pipeline analysis is provided which details all current mRNA candidates at clinical stages. Major companies and alliances are outlined with a focus on each individual program (infectious diseases). Importantly, drawing upon our VacZine Analytics research portfolio, a strategic analysis is included whereby opportunities associated with mRNA technologies are contrasted with the competitive threat level should a new vaccine progress to licensure. This report is ideal for any client wishes to understand the potential significance of this emerging field.

THIS PRODUCT IS A SUMMARY PRESENTATION (~120 slides, .pdf) + MS Excel Worksheets

To order please contact your region account manager, buy “on-line” or order direct at: orders@vaczine-analytics.com

【レポートの目次】

PRODUCT CONTENTS:
Published January 2019 (CAT No: VAMV079)
****This product is composed of one Excel workbook (.xls)1 and an Executive presentation (.pdf)2
Authors note
Table of Contents
Executive summary
[Section] mRNA vaccines – Background
16 slides
[Section] mRNA vaccines – R&D pipeline analysis
mRNA vaccines: pipeline analysis methodology
mRNA pipeline analysis: number of clinical trials
mRNA pipeline analysis: industry vs non-industry clinical trials
mRNA pipeline analysis: cancer indications in clinical trials
mRNA pipeline analysis: infectious disease indications in clinical trials
mRNA pipeline analysis: clinical studies by phase
mRNA pipeline analysis: clinical studies by intervention type
mRNA pipeline analysis: clinical studies by initiation date
mRNA pipeline analysis: key companies with mRNA vaccines in clinical studies
[Section] mRNA vaccines – R&D pipeline analysis of key companies – Infectious diseases
Company 1
Company 2
Company 3
Company 4
Additional companies
Appendices: Back-up and source material
Bibliography
About VacZine Analytics
Disclaimer
Slide number = 120 (.pdf)
Model worksheet number 5 (.xls)
Bibliography ~ 140 references



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[mRNAワクチン(感染症):世界の市場機会分析・予測]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆